|Articles|May 2, 2023
- Pharmaceutical Technology, May 2023
- Volume 47
- Issue 5
- Pages: 12
LNP Formulation for mRNA Therapies
Author(s)Pharmaceutical Technology Editors
Polyplus’ LipidBrick IM21.7 is designed to expand the scope of LNP usage in various therapeutic and oncology applications.
Polyplus’ LipidBrick IM21.7 is a novel cationic lipid nanoparticle (LNP) formulation for messenger RNA therapeutic and vaccine development. The formulation is designed to expand the scope of LNP usage in various therapeutic and oncology applications, as well as prophylactic vaccines.
The LipidBrick is designed to overcome current-generation ionizable lipid challenges used in current LNPs by enabling a wider in-vivo biodistribution and decreasing accumulation in the liver. Proof of concept work demonstrated that it successfully modulates the overall charge of LNPs, improving drug efficiency and formulation stability with no additional safety concerns.
Articles in this issue
over 2 years ago
Using Smart Tools for Smart Developmentover 2 years ago
Frontrunner in Organ-on-a-Chipover 2 years ago
Quality Quartets in Risk-Based Qualificationover 2 years ago
High-Quality Communication Enables High-Quality Drug Productsover 2 years ago
The Next Challenge in Dissolution–Nanoparticlesover 2 years ago
Optimizing the Manufacture of Emerging Therapiesover 2 years ago
Continuous Hot-Melt Extrusion for Poorly Soluble APIsover 2 years ago
Springing Forwardover 2 years ago
On Strike!over 2 years ago
Envisioning Digital Pharma ManufacturingNewsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Related Content
